Latest news with #VOICE
The Irish Sun
23-05-2025
- Entertainment
- The Irish Sun
Saoirse Ronan and TV star husband ‘thrilled' to be expecting first child after opening up on ‘always wanting' family
HOLLYWOOD beauty Saoirse Ronan and her husband Jack Lowden are 'thrilled' to be expecting their first child. The 31-year-old star and her fellow actor partner, 34, Advertisement 4 Saoirse Ronan stunned in a black gown at glam fashion bash Credit: Getty Images - Getty 4 Saoirse and her Slow Horses star husband Jack Lowden got married last summer Credit: PA:Press Association 4 Saoirse is said to be 'thrilled' to be expecting her first child Credit: Alamy The surprise announcement came just hours after Saoirse turned heads as she stepped out in a jaw-dropping black gown for the Louis Vuitton Cruise in A source close to the couple confirmed the news, with both The pair were married in Giving a rare insight into her private life last year, Saoirse told of her Advertisement READ MORE IN SAOIRSE She admitted: 'I became successful when I was quite young. It meant that by the time I found my partner, I'm now at the stage where if it happened, I would like to have a 'I feel fortunate enough that if I step out of this for a minute, I'm hopefully not giving it up forever. But, yeah, I've always wanted that.' The young celebrity couple share a €2.8million home in Advertisement MOST READ IN THE IRISH SUN Exclusive He previously called working with her as 'remarkable'. He said: 'The woman is a force of nature, on- and off-screen, and utterly fearless and a brilliant leader as well.' Watch as Saoirse Ronan shuts down Paul Mescal for talking over her - before leaving star speechless live on TV 'MY VOICE OF REASON' Saoirse gave her reaction to Jack's comments in an interview with Harper's Bazaar, saying: 'When a person you respect as much as I do says that, it means more than anyone else's opinion.' The A-list couple have produced a 2024 adaptation of The Outrun together, which Saoirse starred in and later described her man as 'a lot calmer' than she is as a collaborator. Advertisement She added: 'He's my voice of reason. But as a duo, we've both been on film sets our whole lives, so we have an appreciation of what we're asking actors to do. We always want them to feel safe.' Saoirse joked to radio host 'INCREDIBLY PROUD' Saoirse told the 'So we're putting a lot of time and our energy into that — we're incredibly proud and excited about the reception that that's got. Advertisement 'That's still in the 'And yeah, we're doing great — he's doing the washing right now.' Quizzed elsewhere on whether the pair would appear on screens together again, she laughed: 'Jack didn't want to for a long time, but I have now convinced him that's a great idea. 'I'd really like to do something together on stage.' Advertisement PRIVATE LIVES The young starlets are famously guarded about their private lives and refused to confirm their romance for many years. In 2019, when asked by a reporter: 'Am I allowed to ask if you're going out with the person that everyone thinks you're going out with?', Saoirse replied simply, 'No.' That same year, Jack was asked about their relationship in an interview with ES Magazine but said: 'Oh, I'm not going to talk about that. I don't like talking about that side of life.' At this week's star-studded Advertisement And keeping the look minimalist, the actress wore sandals and her wedding ring as her only accessory. 4 Saoirse and Jack starred in Mary Queen of Scots back in 2018 Credit: Getty Images - Getty
Yahoo
11-05-2025
- Business
- Yahoo
Officials weaken hard-won protections designed to safeguard global resources: 'Raising concerns'
The European Commission has eased an anti-deforestation law to impose less of a burden on companies. Critics of the change are worried that this move will make the law less effective at the expense of the environment. As Reuters reported, the European Union will require less paperwork from companies to prove they are not destroying forests. Starting in December, companies will only need to submit due diligence statements once per year instead of per shipment or batch of goods for sale on the European market. The EU will soon categorize countries as low, standard, or high risk regarding deforestation. Then, it will impose easier compliance requirements on lower-risk countries. This decision is a response to industry complaints and calls from governments, such as the U.S. paper industry, for lighter reporting obligations. However, some people are concerned that easier requirements could lead to increased deforestation. "Reducing the reporting requirements from every batch to merely once a year is the pendulum swinging extremely from one side to the other, raising concerns about how effective monitoring and enforcement can still be," said Antonie Fountain, director of the VOICE Network. The deforestation reporting legislation in the EU bans imports of palm oil, cocoa, beef, soy, and other goods linked to forest destruction. Without strict requirements, laws like this can become less effective in protecting the planet's forests. Forests are essential for maintaining ecological balance because they absorb and store carbon dioxide. This gas would otherwise contribute to air pollution and the planet's overheating. Should the government be allowed to control how restaurants run their business? Never Only in some cases Only for chain restaurants Yes in all cases Click your choice to see results and speak your mind. Meanwhile, anti-deforestation laws often address the livelihoods and rights of indigenous people who rely on forests in daily life. They help preserve native people's ways of life while encouraging sustainable supply chains worldwide. They also hold corporations accountable for environmental destruction if their practices involve clearing forests for sales and profit. Fortunately, many positive actions are occurring worldwide to protect forests. However, companies must be monitored closely to ensure they aren't harming protected forests while producing goods. Elsewhere, such as in Indonesia, the government is working to convert palm oil plantations back into natural forests to preserve the land. In Japan, conservationists are chopping down monoculture plantations to save dying forests. In the U.S., Indigenous communities have collaborated with a nonprofit to protect vulnerable trees like the white oak. As an individual, you can volunteer your time or donate money to forest conservation and restoration organizations that share your values. You can also educate yourself about critical climate issues like deforestation and the benefits of rewilding projects, sharing what you learn with people around you. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
10-05-2025
- Business
- Yahoo
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2025 and recent business highlights. 'We are tremendously encouraged by the early progress of the Vafseo® (vadadustat) launch, having generated $12.0 million in net product revenues in the first quarter. We believe the early success reflects the excitement among physicians of having an alternative treatment for anemia available for their dialysis patients,' said John P. Butler, Chief Executive Officer of Akebia. 'We believe the introduction of Vafseo is one of the strongest drug launches into the dialysis market in many years, certainly since the adoption of transitional drug add-on payment adjustment (TDAPA) reimbursement, and we continue to believe that Vafseo could be a new standard of care for the treatment of anemia due to chronic kidney disease (CKD). Initial usage as expected is in the small and mid-sized dialysis providers and we look forward to continuing to drive adoption across all dialysis providers, large and small.' Vafseo U.S. Commercial Updates: Vafseo net product revenue in Q1 2025 totaled $12.0 million. Through the end of March, more than 640 prescribers wrote a prescription for Vafseo and each prescriber, on average, had written nearly 12 prescriptions. About 1/3 of all prescriptions written were refills and refill data demonstrate an increase in average dose per patient. Through the end of April, the top five dialysis organizations placed Vafseo orders, though most revenue continues to be driven by mid-sized dialysis organizations. Akebia estimates that it has at least 12 months of Vafseo inventory on hand in the U.S. free of potential incremental tariff payments based on its current operating plan. Additional Key Business Highlights: In March, completed an underwritten public offering of 25 million shares priced at $2.00 per share, raising gross proceeds of $50 million. U.S. Renal Care continues enrollment in VOICE, a collaborative clinical trial of Vafseo designed to assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care. Enrollment is now at 75% of the planned trial enrollment of approximately 2,200 patients. Plan to initiate a Phase 3 clinical trial (VALOR) to study the use of vadadustat for treating anemia in late-stage CKD patients who are not on dialysis. Expect the VALOR clinical trial to begin in the second half of 2025. In January, Vafseo was recommended for symptomatic anemia in adults undergoing dialysis for CKD by the United Kingdom (U.K.) National Institute for Health and Care Excellence (NICE), a distinction especially relevant for practitioners and commissioners making care choices for patients in the U.K. and of interest globally. Akebia's partner Medice launched Vafseo in the U.K. Auryxia® (ferric citrate) net product revenue in Q1 2025 totaled $43.8 million. In January 2025, phosphate binders, including Auryxia, were added to the bundled payment for dialysis services and qualified for TDAPA, providing an additional payment for each service in which Auryxia is used. Loss of Auryxia market exclusivity occurred on March 20, 2025. To date, no Abbreviated New Drug Application has been approved for Auryxia, and there is only one authorized generic for Auryxia. In April, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the European Commission to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with CKD. Financial Results Revenues: Total revenues were $57.3 million in the first quarter of 2025 as compared to $32.6 million in the first quarter of 2024, driven by initial sales of Vafseo in the U.S. and an increase in sales of Auryxia. Vafseo net product revenues were $12.0 million in the first quarter of 2025. Vafseo was launched into the U.S. market in the first quarter of 2025. Auryxia net product revenues were $43.8 million in the first quarter of 2025 as compared to $31.0 million in the first quarter of 2024. License, collaboration and other revenues were $1.5 million in the first quarter of 2025 as compared to $1.6 million in the first quarter of 2024. Cost of Goods Sold: Cost of goods sold was $7.6 million in the first quarter of 2025 as compared to $11.6 million in the first quarter of 2024. A key driver of this decrease was the fact that Akebia carried a non-cash intangible amortization charge of $9.0 million per quarter through the fourth quarter of 2024. Of note, Vafseo-related cost of goods sold is derived from pre-launch inventory which does not include the full cost of manufacturing, as a portion of those inventory-related costs were recorded as R&D expenses in the period incurred prior to Vafseo's approval in the U.S. Also, during the first quarter of 2024, Akebia realized a $3.7 million benefit due to its ability to sell Auryxia inventory previously written down as excess inventory. Research & Development Expenses: Research and development expenses were $9.8 million in the first quarter of 2025 as compared to $9.7 million in the first quarter of 2024. Selling, General & Administrative Expenses: Selling, general and administrative expenses were $25.7 million in the first quarter of 2025 as compared to $25.4 million in the first quarter of 2024. Net Income (Loss): Net income was $6.1 million in the first quarter of 2025 compared to a net loss of $18.0 million in the first quarter of 2024. Net income in the first quarter of 2025 was driven by the increase in net product revenues, including the introduction of Vafseo sales in the U.S., which was partially offset by $5.4 million in interest expense related to the settlement royalty liability in connection with the July 2024 Vifor Termination and Settlement Agreement. Cash Position: Cash and cash equivalents as of March 31, 2025 were approximately $113.4 million compared to $51.9 million at December 31, 2024, which includes $46.5 million in net proceeds raised from an underwritten public offering of common stock completed in March. Akebia believes that it is financed to achieve profitability based on its current operating plan, which includes pursuing label expansion for Vafseo and advancing other existing programs. Conference Call Akebia will host a conference call on Thursday, May 8 at 8:00 a.m. Eastern Time to discuss first quarter 2025 earnings. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the conference call will be available via the 'Investors' section of Akebia's website at: An online archive of the webcast can be accessed via the Investors section of Akebia's website at approximately two hours after the event. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at which does not form a part of this release. About Vafseo® (vadadustat) tablets Vafseo® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries. INDICATION VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. In patients with anemia due to CKD not on dialysis. IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS. VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks. Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. CONTRAINDICATIONS Known hypersensitivity to VAFSEO or any of its components Uncontrolled hypertension WARNINGS AND PRECAUTIONS Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular AccessA rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis. HepatotoxicityHepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease. HypertensionWorsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed. SeizuresSeizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency. Gastrointestinal (GI) ErosionGastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present. Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa. MalignancyVAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies. ADVERSE REACTIONS The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea. DRUG INTERACTIONS Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron. Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders. BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction. Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg. USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. Lactation: Breastfeeding not recommended until two days after the final dose. Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease. Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide. Forward-Looking Statements Statements in this press release regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia's plans and expectations with respect to the commercial launch of Vafseo, including that its early success reflects excitement among physicians of having an alternative treatment for anemia available for dialysis patients; Akebia's statements about the strength of the Vafseo launch; Akebia's beliefs and plans to establish Vafseo as the new standard of care for the treatment of anemia due to CKD; Akebia's expectations as to usage and its plans to drive adoption across all dialysis providers; Akebia's estimates about the amount of Vafseo inventory on hand in the U.S. that is free of potential incremental tariff payments based on its current operating plan; Akebia's plans and expectations with respect to a Phase 3 clinical trial (VALOR) to study the use of vadadustat for treating anemia in late-stage CKD patients who are not on dialysis and the timing thereof; Akebia's expectations regarding the VOICE trial; and Akebia's expectations that it is financed to achieve profitability based on its current operating plan, which includes pursuing label expansion for Vafseo and advancing other existing programs and assumptions related thereto. The terms "intend," "believe," "plan," "goal," "potential," "anticipate, "estimate," "expect," "future," "will," "continue," derivatives of these words, and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to, risks associated with: the commercial availability of Vafseo; the potential demand and market potential and acceptance of, as well as coverage and reimbursement related to, Auryxia® and Vafseo, including estimates regarding the potential market opportunity; the competitive landscape for Auryxia and Vafseo, including generic entrants and the timing thereof; the ability of Akebia to attract and retain qualified personnel; Akebia's ability to achieve and maintain profitability and to maintain operating expenses consistent with its operating plan; decisions made by health authorities, such as the FDA, with respect to regulatory filings and other interactions; the potential therapeutic benefits, safety profile, and effectiveness of Vafseo; the results of preclinical and clinical research; manufacturing, supply chain and quality matters and any recalls, write-downs, impairments or other related consequences or potential consequences; early termination of any of Akebia's collaborations; and changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Annual Report on Form 10-K for the year ended December 31, 2024, and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and, except as required by law, Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Akebia Therapeutics®, Auryxia® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc. and its affiliates. Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@ AKEBIA THERAPEUTICS, INC. Unaudited Condensed Consolidated Statements of Operations Three Months Ended March 31, (in thousands, except per share data) 2025 2024 Revenues Product revenue, net $ 55,791 $ 31,009 License, collaboration and other revenue 1,545 1,598 Total revenues 57,336 32,607 Cost of goods sold Cost of product and other revenue 7,625 2,594 Amortization of intangible asset — 9,011 Total cost of goods sold 7,625 11,605 Operating expenses Research and development 9,754 9,731 Selling, general and administrative 25,742 25,438 License 701 711 Restructuring — 58 Total operating expenses 36,197 35,938 Income (loss) from operations 13,514 (14,936 ) Other expense, net (7,557 ) (2,403 ) Change in fair value of warrant liability 155 (129 ) Loss on extinguishment of debt — (517 ) Net income (loss) $ 6,112 $ (17,985 ) Net income (loss) per share - basic $ 0.03 $ (0.09 ) Net income (loss) per share - diluted $ 0.03 $ (0.09 ) Weighted-average number of common shares - basic 235,497,720 204,955,151 Weighted-average number of common shares - diluted 241,602,853 204,955,151 Unaudited Selected Balance Sheet Data (in thousands) March 31, 2025 December 31, 2024 Cash and cash equivalents $ 113,374 $ 51,870 Working capital $ 112,555 $ 32,917 Total assets $ 310,185 $ 220,670 Total stockholders' equity (deficit) $ 24,581 $ (49,185 )
Japan Today
21-04-2025
- Politics
- Japan Today
Homeland Security Secretary Noem's purse stolen at DC restaurant, officials say
Homeland Security Secretary Kristi Noem speaks during a news conference to announce the re-launch of the VOICE office, Victims of Immigration Crime Engagement, with families of victims behind her, at the Immigration and Customs Enforcement headquarters, Wednesday, April 9, 2025, in Washington. (AP Photo/Alex Brandon) Homeland Security Secretary Kristi Noem's purse was stolen at a Washington, DC restaurant Sunday night, according to department officials. The department in an email said Noem had money in her purse to buy gifts for her children and grandchildren and to pay for Easter dinner and other activities. The department in an email didn't specify what was stolen, but CNN — which was first to report the story — said the thief took about $3,000 in cash, as well as Noem's keys, driver's license, passport, checks, makeup bag, medication and Homeland Security badge. The Homeland Security Secretary is protected by U.S. Secret Service agents. The Secret Service referred questions about the incident to Homeland Security headquarters. © Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Yahoo
10-04-2025
- Politics
- Yahoo
DHS reopens office to support victims of crimes committed by undocumented migrants
April 10 (UPI) -- The Trump administration has relaunched the Victims of Immigration Crime Engagement office to offer resources and support to families who are victims of crimes committed by undocumented migrants. Department of Homeland Security Secretary Kristi Noem made the announcement Wednesday during a press conference at ICE headquarters while being surrounded by victims of such crimes. "With the relaunching of the VOICE office we are giving victims and their families access to resources and support services," she said in a statement emailed to UPI. "President [Donald] Trump and I will continue to remove criminal illegal aliens from our streets and make America safe again." The office's launch is part of the Trump administration's crackdown on both legal and illegal immigration. Since returning to office, Trump has sought to remove undocumented migrants from the country and has come under criticism -- and attracted lawsuits -- over sending hundreds of alleged gang members to a notorious prison in El Salvador. According to DHS, the new office will provide victims with information on immigration enforcement and removal processes, migrants in U.S. Immigration and Customs Enforcement custody and criminal or immigration history about migrants. Victims will also be told how to provide a victim impact statement in applicable cases and given access to social service professionals and contacts for local resources and service providers. "I'm extremely proud of ICE's entire workforce -- the officers and agents on the ground who are enforcing immigration law fairly, the support staff who pull these operations together and handle logistics and those who help shine a light on those who have suffered harm at illegal aliens' hands," Noem said. Trump first launched VOICE in 2017, despite criticism from opponents who said it would only further vilify undocumented immigrants. Trump's predecessor, President Joe Biden, terminated the program in 2021 and replaced it with the Victims Engagement and Services Line to provide a more comprehensive and inclusive victim support system to ensure all victims, regardless of the immigration statues of the victim or perpetrator, receive help. Studies have repeatedly shown that undocumented immigrants commit fewer crimes than those born in the United States.
